AcelRx Pharmaceuticals Inc. (ACRX) Plunges 10.26% on October 17

Equities Staff |

AcelRx Pharmaceuticals Inc. (ACRX) had a rough trading day for Tuesday October 17 as shares tumbled 10.26%, or a loss of $-0.2 per share, to close at $1.75. After opening the day at $1.90, shares of AcelRx Pharmaceuticals Inc. traded as high as $1.95 and as low as $1.70. Volume was 4.34 million shares over 9,384 trades, against an average daily volume of 1.89 million shares and a total float of 45.38 million.

As a result of the decline, AcelRx Pharmaceuticals Inc. now has a market cap of $79.42 million. In the last year, shares of AcelRx Pharmaceuticals Inc. have traded between a range of $5.75 and $1.90, and its 50-day SMA is currently $3.52 and 200-day SMA is $2.95.

For a complete fundamental analysis of AcelRx Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for ACRX.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of therapies for the treatment of acute pain.

AcelRx Pharmaceuticals Inc. is based out of Redwood City, CA and has some 43 employees. Its CEO is Vincent J. Angotti.

AcelRx Pharmaceuticals Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on AcelRx Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: ACRX’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

AfterMaster Inc

Studio One Media Inc is a diversified media and technology company. It is engaged in the development and commercialization of proprietary, edge audio and video technologies for professional and consumer…

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

The Green Organic Dutchman

The Green Organic Dutchman Ltd. ("TGOD") produces farm grown, organic cannabis for medical use. The company grows its high quality organic cannabis in small batches using craft growing, all natural…